Pfizer

PFE · NYSE

$30.11+$0.67 (+2.28%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $29.44

PFE analyst rating

HoldConsensus of 15 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy6
Hold8
Underperform1
Sell0

12-month price target · 31 analysts

Average $29.23 (−2.9% downside)

Low: $24.24
Now: $30.11
High: $37.54

Upgrades and downgrades

The latest rating actions, newest first

PFE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 9, 2026	Maintains	Neutral	$28.00 → $30.00	65%
Cantor Fitzgerald	Oct 8, 2026	Maintains	Neutral	$27.00 → $28.00	64%
Scotiabank	Oct 6, 2026	Maintains	Sector Outperform	$30.00 → $33.00	48%
HSBC	Sep 10, 2026	Maintains	Hold	$28.00 → $30.00	59%
Guggenheim	Aug 7, 2026	Maintains	Buy	$35.00 → $31.00	66%
BMO Capital	Jul 13, 2026	Maintains	Outperform	$34.00 → $30.00	54%
Guggenheim	Jul 13, 2026	Maintains	Buy	$36.00 → $35.00	66%
B of A Securities	Jul 10, 2026	Maintains	Neutral	$27.00 → $26.00	56%
JP Morgan	Jul 8, 2026	Maintains	Neutral	$30.00 → $28.00	65%
Cantor Fitzgerald	Jul 6, 2026	Maintains	Neutral	$27.00	64%

The case for and against

Updated Oct 16, 2026

Bull case

Pfizer is viewed favorably because its products, pipeline, and execution have continued to exceed expectations, supporting confidence in the company’s ability to compound value. As one of the world’s largest pharmaceutical firms with roughly $60 billion in annual sales, it benefits from a diversified mix led by prescription drugs and vaccines, including Prevnar 13, Vyndamax, and Eliquis, while international sales contribute 40% of total sales and emerging markets add further growth support. The outlook is also anchored by management’s expectation of a return to growth by the end of the decade, driven by R&D pipeline maturation, completed business development initiatives, and strong commercial execution.

Bear case

Pfizer is facing a negative fundamental setup because its 2026 guidance already reflects about a $1.1 billion year-over-year revenue hit from loss of exclusivity, signaling sustained erosion in the core portfolio. Prevnar weakness, tied to declining vaccination rates, lower birth rates, and U.S. vaccine policy, adds pressure to a key franchise, while competition from lower-priced, higher-rebate, or more effective drugs raises the risk of pricing and volume loss across immunology, oncology, vaccines, and rare diseases. The outlook is further weighed down by generic and biosimilar competition, potential delays or failures in pipeline assets, and macro risks from drug-pricing reform and tariff policy that could dampen investor interest in large-cap biopharma.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.